Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial
Key facts
- Who runs it
- Samer Gawrieh
- Where
- Cleveland, Dallas, Indianapolis, Louisville, Richmond, and Rochester, United StatesSee the 6 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 216 people, planned
- Started
- 27 Jan 2026
- Expected to end
- Dec 2029
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- IL-22
- Prednisone
- Acamprosate
- Prednisone placebo
- IL-22 (F-652) Placebo
- Motivational Interviewing (MI)
- Motivational Enhancement Therapy (MET)
- Usual Care
- Record updated
- 15 July 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Age ≥18, <70
- MELD 20-35
- Definitive or probable diagnosis of sAH as defined by the NIAAA criteria4, 5 A. Onset of jaundice (defined as serum total bilirubin >3 mg/dL) within the prior 8 weeks B. Ongoing average consumption of > 40 gm (for females) and > 60 gm (for males) alcohol daily for 6 months or more with less than 8 weeks of abstinence before onset of jaundice; OR If, in the investigator's judgment, alcohol use may have been underreported, available clinical evidence-including collateral history, medical records, prior documentation of alcohol use, alcohol biomarkers such as PEth, or other relevant evidence-indicates that the participant met the protocol-defined alcohol consumption requirement within the 8 weeks before screening; AST > 50 IU/L, D. AST: ALT > 1.5 E. ALT and AST values < 400 IU/L F. Liver biopsy findings consistent with AH; *In patients with possible AH or AH with confounding factors such as possible ischemic hepatitis, possible DILI, uncertain history of alcohol use (e.g., patient denies excessive alcohol use), and atypical/abnormal laboratory tests (e.g., AST < 50 IU/L or > 400 IU/L, AST/ALT ratio < 1.5), antinuclear antibody > 1:160 or SMA > 1:80, a standard of care liver biopsy will be considered during current hospital admission to confirm AH and exclude competing etiologies
- Females of childbearing (reproductive) potential must have a negative serum or urine pregnancy test at screening
Who cannot take part
- Active listing for liver transplantation before screening
- Prior exposure to systemic corticosteroid (glucocorticoid) or TNF-alpha inhibitors for more than 4 days within the previous 30 days prior to screening, specifically for the treatment of sAH
- Significant concomitant medical illnesses (such as uncontrolled congestive heart failure or COPD or progressive multi-organ failure) as determined by the study investigator
- Uncontrolled HBV, HIV, or HCV infection with persistent viremia. However, subjects with controlled (undetectable viral load) HIV and HBV on viral suppressive therapies will be enrolled and subjects with history of HCV will be enrolled if they have evidence of SVR within one year prior to enrollment
- Unwillingness to either abstain from sexual intercourse, or if sexually active, use a reliable method of birth control during the study and for at least 30 days after the last dose of the study medication. Examples of acceptable birth control methods include double barrier method such as condom and occlusive cap (diaphragm or cervical cap) with spermicidal foam/gel/film/cream/suppository; birth control pills, patches, injections, or implants; intrauterine device (IUD); vasectomy and tubal ligation
- Uncontrolled infection (persistent positive blood or other body fluid cultures despite 48 hours of antibiotic therapy)
- Clinically active C. diff infection
- Evidence of other liver diseases (such as autoimmune hepatitis, primary biliary cholangiopathy, primary sclerosing cholangitis, ischemic, sepsis- or drug-induced liver disease)
- History or presence of cancer (including hepatocellular carcinoma) other than non-melanoma skin cancer
- Uncontrolled mental illness as determined by the study investigator
- Uncontrolled diabetes mellitus with A1c > 9
- Known allergy or intolerance to therapeutic agents to be tested
- Participant has any condition or circumstance that adversely affects the participant, could cause noncompliance with treatment or visits, may impact the interpretation of clinical data, could cause bias, or may otherwise contraindicate the participant's participation in the study
- Renal failure defined by estimated GFR (CKD-EPI) <35 mL/min
- Clinically significant pancreatitis- abdominal pain, elevated lipase (> 3 X ULN), and at least edema of pancreas with fat-stranding on CT scan
- Active gastrointestinal bleeding defined as hematemesis or melena with a decrease in hemoglobin more than 2 g/dl in 24 hours due to gastrointestinal bleeding, or with a decrease in mean arterial BP to < 65 mmHg
- MELD score <20 or > 35
- Progressive hemodynamic compromise requiring intravenous pressors
- Pneumonia as evidenced by clinical and/or radiological examination (will not perform radiology if not indicated by clinical exam)
- Active illicit opiates, cocaine, ketamine, or methamphetamine use in the last 30 days via patient report or medical chart review
- Pregnancy or breastfeeding
- Unwillingness to stop alcohol use and to undergo AUD treatment
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
- Cleveland ClinicCleveland, United StatesContact: Srinivasan Dasarathy, MD (principal investigator)Taking people
- University of Texas Southwestern Medical SchoolDallas, United StatesContact: Mack Mitchell, MD (principal investigator)Taking people
- Indiana UniversityIndianapolis, United StatesContact: Raj Vuppalanchi, MD (principal investigator)Taking people
- University of LouisvilleLouisville, United StatesContact: Ashwani Singal, MD (principal investigator)Taking people
- Virginia Commonwealth UniversityRichmond, United StatesContact: Arun Sanyal, MD (principal investigator)Taking people
- Mayo ClinicRochester, United StatesContact: Vijay Shah, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
This is a multicenter, randomized, double-blinded, placebo-controlled trial focused on the treatment of severe alcohol-associated hepatitis (sAH) and alcohol use disorder (AUD).
Read full original descriptionShow less
The primary purpose of the study is to determine whether subjects receiving sAH therapy in addition to AUD treatments will have better alcohol and liver-related outcomes at 6 months compared to sAH therapy plus usual care for AUD. Patients assigned to the AUD treatment will receive Acamprosate and counseling whereas those assigned to AUD standard care will receive brief advice and referral to a 12-step program.
The secondary purpose of the study is to determine if F-652 is safe and effective in treating sAH when compared to prednisone. Subjects will receive F-652 on days 1 and 7 or prednisone for 28 days. Outcomes will be measured by overall survival at 90 days.
The 4 groups in the trial
- IL-22 (F-652), Prednisone Placebo, Acamprosate, MI and METExisting treatment, for comparison
F-652 on days 1 and 7 and matching placebos for prednisone for 28 days and acamprosate for 6 months. MI will be delivered during the hospitalization; MET sessions will be delivered in the first 3 months
Treatment: IL-22, Acamprosate, Prednisone placebo, Motivational Interviewing (MI), and Motivational Enhancement Therapy (MET)
- IL-22 (F-652), Prednisone Placebo, and usual careExisting treatment, for comparison
F-652 on days 1 and 7 and matching placebo for prednisone for 28 days and usual care for AUD.
Treatment: IL-22, Prednisone placebo, and Usual Care
- Prednisone, IL-22 (F-652) Placebo, Acamprosate, MI, and METExisting treatment, for comparison
Prednisone for 28 days and matching placebos for F-652 on days 1 and 7 and acamprosate for 6 months. MI will be delivered during the hospitalization; MET sessions will be delivered in the first 3 months
Treatment: Prednisone, Acamprosate, IL-22 (F-652) Placebo, Motivational Interviewing (MI), and Motivational Enhancement Therapy (MET)
- Prednisone, IL-22 (F-652) Placebo, and usual careExisting treatment, for comparison
Prednisone for 28 days and matching placebo for F-652 on days 1 and 7 and usual care for AUD.
Treatment: Prednisone, IL-22 (F-652) Placebo, and Usual Care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07060638, who can take part
- Record updated
- 15 July 2026